RADNOR, PA / ACCESSWIRE / September 25, 2018 / Kaskela Law LLC is investigating Menlo Therapeutics Inc.
(NASDAQ: MNLO) ("Menloc" or the "Company") on behalf of investors. The investigation concerns whether Menlo and certain of its
officers and/or directors have engaged in securities fraud or other unlawful business practices, and whether Menlo investors have
been harmed as a result.
Menlo investors are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 - 1740, or skaskela@kaskelalaw.com, to discuss this investigation and their legal rights and options.
Investors may also receive additional information about this investigation online at http://kaskelalaw.com/case/menlo-therapeutics/.
Menlo is a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus
associated with various underlying dermatologic conditions and for the treatment of refractory chronic cough.
On or around January 24, 2018, Menlo completed an initial public offering ("IPO") of common stock, selling over 8 million shares
of stock to investors at $17.00 per share, for gross proceeds of $136.9 million. By February 2018, shares of the Company's common
stock had increased in value to over $30.00 per share.
On April 6, 2018, the Company disclosed top-line results from MTI-103 (ATOMIK), the Phase 2 clinical trial of serlopitant for
the treatment of pruritus in adults and adolescents with a history of atopic dermatitis. Therein the Company reported that the
study "did not meet its primary or key secondary efficacy endpoints with no statistically significant difference demonstrated
between the serlopitant treated groups and the placebo treated group." Among other things, Menlo's CEO also disclosed how "the
results in this Phase 2 trial of pruritus associated with atopic dermatitis did not reach statistical significance and did not show
the same magnitude of treatment effect as in our prior pruritus studies."
Following this news, shares of the Company's common stock declined$27.05 per share, or over 75%, to close on April
9, 2018 at $8.17 per share.
Menlo investors with financial damages are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.) at (888) 715 - 1740,
or skaskela@kaskelalaw.com, to discuss this investigation and their legal rights and
options. Investors may also receive additional information about this investigation online at http://kaskelalaw.com/case/menlo-therapeutics/.
Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of
investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com. This notice may constitute attorney advertising in certain jurisdictions.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
(484) 258 - 1585
(888) 715 - 1740
info@kaskelalaw.com
www.kaskelalaw.com
SOURCE: Kaskela Law LLC
